HOPEN LIFE SCIENCE VENTURES
Hopen Therapeutics is a private investment and management firm focused on helping early- to mid-stage life science developments achieve commercial success. We're interested in promising pharmaceutical and healthcare concepts, and offer idea owners three key advantages: ample funding, development and managerial expertise, and a broad network of industry relationships.
HOPEN LIFE SCIENCE VENTURES
Status:
Active
Contact:
(440) 385-4225
Email Addresses:
[email protected]
Technology used in webpage:
Euro Microsoft Exchange Online Office 365 Mail
Similar Organizations
BioAdvance
BioAdvance is a Pennsylvania-based venture capital firm that provides funding to life sciences startups.
Venrock
Venrock is a venture capital firm investing in technology and healthcare companies.
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2017-04-11 | Cirius Therapeutics | Hopen Life Science Ventures investment in Series A - Cirius Therapeutics | 40 M USD |
2015-09-10 | Delphinus Medical Technologies | Hopen Life Science Ventures investment in Series C - Delphinus Medical Technologies | 39.5 M USD |
2015-06-09 | NeoChord | Hopen Life Science Ventures investment in Series C - NeoChord | 20 M USD |
2014-09-11 | Prevacept Infection Control | Hopen Life Science Ventures investment in Venture Round - Prevacept Infection Control | 11.22 M USD |
2014-04-21 | Sierra Oncology | Hopen Life Science Ventures investment in Series D - Sierra Oncology | 59.5 M USD |
2014-04-04 | Bjond | Hopen Life Science Ventures investment in Series A - Bjond | 3.25 M USD |
2012-10-16 | Tolera Therapeutics | Hopen Life Science Ventures investment in Series B - Tolera Therapeutics | 5.5 M USD |
2011-07-18 | Trapelo Health | Hopen Life Science Ventures investment in Series B - Trapelo Health | 7.2 M USD |
2010-10-24 | Metabolic Solutions Development | Hopen Life Science Ventures investment in Series D - Metabolic Solutions Development | 23.5 M USD |
2010-01-01 | Nymirum | Hopen Life Science Ventures investment in Grant - Nymirum | 2.79 M USD |